Mount Sinai Health System, New York City's largest academic medical system, recently described how it is working with a company called mphrX to enable real-time clinical data sharing designed to meet the 21st Century Cures Act requirements.
The 21st Century Cures Act requires healthcare providers to enable access to clinical data using SMART on FHIR as well as Bulk-FHIR API standards.
Minerva, a healthcare data platform as a service from mphrX, will integrate with the clinical source systems at Mount Sinai to create a real-time longitudinal health record. The platform will provide secure and standardized access to clinical data using SMART on FHIR R4 and Bulk-FHIR APIs.
“Part of what drew us to partner with mphrX was our shared commitment to the FHIR standard — the best chance for the industry to eliminate the technical friction when sharing data at scale,” explained Mike Berger, vice president and chief data and analytics officer at Mount Sinai Health Partners and vice president, enterprise data at Mount Sinai Health System, in a statement. “While the 21st Century Cures Act provides a great tailwind, our enterprise data strategy clearly lays out the need for a modern and high-performing endpoint to collaborate on data safely and efficiently. We’re excited to be at the forefront of FHIR adoption and can’t wait to see the innovations this will spawn.”
Mount Sinai will leverage the technology to solve multiple data-sharing needs in its ecosystem, including sharing clinical data with payers, third-party technology companies, internal data science teams and partners. The health system will also receive data from external parties to create a more holistic view of their patient’s health and socioeconomic indicators.
“We believe delivering true value-based care has become a necessity,” said Varun Anand, co-founder & chief operating officer of mphrX, in a statement. “The ability to unify healthcare data, securely share and derive insights is the core foundation to delivering better value to patients. This collaboration is a great example of how meeting Cures Act requirements can also accelerate innovation and in turn, improve patient care and outcomes.”
